ALKERMES | ALKS - Zysk Brutto Na Sprzedaży





Zysk Brutto Na Sprzedaży Zmiana Data
AbbVie USD 12.54B 474M 2026-03
Acadia Pharmaceuticals USD 243.27M 14.49M 2026-03
ALKERMES USD 331.33M 7M 2026-03
Amgen USD 6.89B 415M 2025-12
Biogen USD 1.82B 169.5M 2026-03
BioMarin Pharmaceutical USD 571.21M 141.8M 2026-03
Bristol-Myers Squibb USD 8.41B 381M 2025-12
Coherus Biosciences USD 8.7M 853K 2025-12
Eli Lilly USD 15.92B 1.33B 2025-12
Gilead Sciences USD 5.52B 791M 2026-03
Heron Therapeutics USD 29.47M 3.17M 2025-12
Ionis Pharmaceuticals USD 243M 48M 2026-03
J&J USD 17.24B 642M 2026-03
Merck USD 10.85B 2.57B 2025-12
Minerva Neurosciences -4.27M 26.79M 2024-12
Nektar Therapeutics USD 21.81M 8.06M 2025-12
Neurocrine Biosciences USD 800.7M 12.8M 2026-03
Otsuka Holdings JPY 456.25B 1.16B 2026-03
Pfizer USD 11.04B 1.24B 2026-03
Regeneron Pharmaceuticals USD 2.94B 363.7M 2026-03
Vertex Pharmaceuticals USD 2.6B 121.7M 2026-03